Loading patent…
AssigneeSchool Juridical Person Kitasato Institute
InventorsTakashi Fukuyama, Hitoshi Yamazaki, Mariko Ogi, Noritada Kobayashi, Yoshinobu Ichiki, Masahiko Hatakeyama
Estimating the term…
Provided is a monoclonal antibody or a fragment thereof in which heavy-chain complementarity-determining regions (CDRs) 1 to 3 respectively consist of amino acid sequences of SEQ ID NOs: 2 to 4 and light-chain CDRs 1 to 3 respectively consist of amino acid sequences of SEQ ID NOs: 5 to 7; a monoclonal antibody or a fragment thereof in which heavy-chain CDRs 1 to 3 respectively consist of amino acid sequences obtained by deleting, substituting, or adding one or several amino acids in the amino acid sequences of SEQ ID NOs: 2 to 4 and light-chain CDRs 1 to 3 respectively consist of amino acid sequences obtained by deleting, substituting, or adding one or several amino acids in the amino acid sequences of SEQ ID NOs: 5 to 7, and which has binding properties to a KK-LC-1 protein; or a monoclonal antibody or a fragment thereof which competes with the monoclonal antibody or a fragment thereof in which the heavy-chain CDRs 1 to 3 respectively consist of the amino acid sequences of SEQ ID NOs: 2 to 4 and the light-chain CDRs 1 to 3 respectively consist of the amino acid sequences of SEQ ID NOs: 5 to 7, and has binding properties to the KK-LC-1 protein.
A monoclonal antibody or an antigen binding fragment thereof that binds Kitakyushu lung cancer antigen-I (KK-LC-1), wherein the antibody or antigen binding fragment thereof comprises:
A hybridoma cell line deposited at the National Institute of Technology and Evaluation under accession number NITE BP-02527.
Dependencies are inferred from the claim text.